19
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Methods and compositions for treating hepatitis C virus

Pages 1289-1291 | Published online: 25 Feb 2005
 

Abstract

Hepatitis C virus infects an estimated 1 – 2% of the population worldwide. The majority of those infected will suffer major liver associated disease or death within the next 15 years unless new and more effective therapies are discovered. The two most promising viral targets for intervention at present are the NS3 serine protease and the NS5B RNA-dependent RNA polymerase (RdRp). In this patent, Novirio Pharmaceuticals and Universita Degli Studi di Cagliari claim the application of ribonucleoside analogues as inhibitors of the HCV RdRp.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.